Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review (Q38139811)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review |
scientific article |
Statements
1 reference
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review (English)
1 reference
Jens Köhler
1 reference
Martin Schuler
1 reference
19 August 2013
1 reference
1 reference
36
1 reference
9
1 reference
510-518
1 reference
Identifiers
1 reference
1 reference